

- a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and
- b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.

11. A method of claim 10, wherein the probe comprises at least 60 contiguous nucleotides.
12. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 8, the method comprising:
  - a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and
  - b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.
13. A composition comprising an effective amount of a polypeptide of claim 1 and an acceptable excipient.
14. A method for screening a compound for effectiveness as an agonist of a polypeptide of claim 1, the method comprising:
  - a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
  - b) detecting agonist activity in the sample.
15. A method for screening a compound for effectiveness as an antagonist of a polypeptide of claim 1, the method comprising:

16. A method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a polynucleotide sequence of SEQ ID NO:2, the method comprising:

- a) exposing a sample comprising the target polynucleotide to a compound, under conditions suitable for the expression of the target polynucleotide,
- b) detecting altered expression of the target polynucleotide, and
- c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.

17. A method for assessing toxicity of a test compound, said method comprising:

- a) treating a biological sample containing nucleic acids with the test compound;
- b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide of claim 8 under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 8 or fragment thereof;
- c) quantifying the amount of hybridization complex; and
- d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

18. A method for treating a disease or condition associated with decreased expression of functional HGST, comprising administering to a patient in need of such treatment the composition of claim 13.

19. A composition comprising an agonist compound identified by a method of claim 14 and

20. A method for treating a disease or condition associated with decreased expression of functional HGST, comprising administering to a patient in need of such treatment a composition of claim 19.